Loading Panacea Biotec…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 200 | 167 | 165 | 141 | 167 |
| Operating profit | -2 | -5 | 3 | -26 | -10 |
| Operating margin | -1.1% | -3.2% | 2.0% | -18.5% | -5.7% |
| Net profit | 2 | 1 | 4 | -14 | 4 |
| Net margin | 1.2% | 0.3% | 2.4% | -9.9% | 2.4% |
| EPS (₹) | 0.38 | 0.08 | 0.65 | -2.27 | 0.66 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 610 | 493 | 552 | 457 |
| Operating profit | -33 | -56 | -44 | -106 |
| Operating margin | -5.4% | -11.3% | -8.0% | -23.1% |
| Net profit | -5 | -8 | -1 | -33 |
| Net margin | -0.9% | -1.7% | -0.2% | -7.3% |
| EPS (₹) | -0.88 | -1.37 | -0.19 | -5.43 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 1,262 | 1,290 | 1,241 | 1,271 |
| Total liabilities | 433 | 459 | 403 | 431 |
| Shareholders’ equity | 835 | 835 | 842 | 844 |
| Total debt | 15 | 15 | 15 | 20 |
| Cash & equivalents | 57 | 51 | 47 | 40 |
| Debt / equity | 0.02 | 0.02 | 0.02 | 0.02 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 17 | -27 | 3 | -422 |
| Capital expenditure | -54 | -50 | -83 | -41 |
| Free cash flow | -37 | -78 | -79 | -463 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | -0.6% | -1.0% | -0.1% | -3.9% |
| Return on assets | -0.4% | -0.6% | -0.1% | -2.6% |
| Net margin | -0.9% | -1.7% | -0.2% | -7.3% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for PANACEABIO. Finnhub coverage is limited for some India-listed stocks.